In a future study, it would be worth determining whether the systemic treatment of FPP can be as potent as antidiabetic effects versus the current standard of care (e.g., metformin, GLP1R agonists, and/or SGLT2 inhibitors) or that FPP acts synergistically with these compounds when given chronically in a proper preclinical model of T2D. Here, SLC5A2 is linked to type 2 diabetes mellitus.